Carrie E Jung1, Shawn A Menefee2, Gouri B Diwadkar2. 1. Department of Obstetrics and Gynecology; Division of Urogynecology, Kaiser Permanente, Southern California, San Diego, CA, USA. jung.carrie@gmail.com. 2. Department of Obstetrics and Gynecology; Division of Urogynecology, Kaiser Permanente, Southern California, San Diego, CA, USA.
Abstract
PURPOSE: Our objectives are to (1) identify predictors of treatment success in women with overactive bladder (OAB) after 1 year of percutaneous tibial nerve stimulation (PTNS) maintenance therapy, (2) identify trends in success rates during that 1 year, and (3) assess maintenance treatment adherence. MATERIALS AND METHODS: A retrospective study of 141 women with OAB was performed with the definition of success based on a Patient Global Impression-Improvement (PGI-I) score of 1 ("very much better") or 2 ("much better") or a PGI-I score of 1, 2, or 3 ("a little better"). Multivariable logistic regression was performed to identify factors associated with treatment response and the Cochrane-Armitage trend test to identify changes in the scores over time. RESULTS: After completing 12 weekly treatments, 141 women initiated maintenance therapy with a mean treatment interval of 29 days. At 1 year, 75/141 (53.2%) had discontinued treatment. Those adherent with treatment had a sustained treatment response, with 66.2% of women reporting a PGI-I score of 1, 2 and 92.3% reporting a PGI-I score of 1, 2, or 3 at 1 year. Considering those women who discontinued maintenance therapy as treatment failures, the success rate of 1 year of maintenance therapy ranged from 30.7%-42.9%. No clinical factors were found to be predictive of maintenance treatment success or failure. CONCLUSIONS: Although an effective treatment for those adherent, discontinuation rates of PTNS maintenance therapy at 1 year are high. Given the low numbers of women referred to maintenance therapy, and the high discontinuation rates, long-term PTNS treatment may be feasible for only a minority of women with OAB.
PURPOSE: Our objectives are to (1) identify predictors of treatment success in women with overactive bladder (OAB) after 1 year of percutaneous tibial nerve stimulation (PTNS) maintenance therapy, (2) identify trends in success rates during that 1 year, and (3) assess maintenance treatment adherence. MATERIALS AND METHODS: A retrospective study of 141 women with OAB was performed with the definition of success based on a Patient Global Impression-Improvement (PGI-I) score of 1 ("very much better") or 2 ("much better") or a PGI-I score of 1, 2, or 3 ("a little better"). Multivariable logistic regression was performed to identify factors associated with treatment response and the Cochrane-Armitage trend test to identify changes in the scores over time. RESULTS: After completing 12 weekly treatments, 141 women initiated maintenance therapy with a mean treatment interval of 29 days. At 1 year, 75/141 (53.2%) had discontinued treatment. Those adherent with treatment had a sustained treatment response, with 66.2% of women reporting a PGI-I score of 1, 2 and 92.3% reporting a PGI-I score of 1, 2, or 3 at 1 year. Considering those women who discontinued maintenance therapy as treatment failures, the success rate of 1 year of maintenance therapy ranged from 30.7%-42.9%. No clinical factors were found to be predictive of maintenance treatment success or failure. CONCLUSIONS: Although an effective treatment for those adherent, discontinuation rates of PTNS maintenance therapy at 1 year are high. Given the low numbers of women referred to maintenance therapy, and the high discontinuation rates, long-term PTNS treatment may be feasible for only a minority of women with OAB.
Authors: Kathryn L Burgio; Patricia S Goode; Julie L Locher; Mary G Umlauf; David L Roth; Holly E Richter; R Edward Varner; L Keith Lloyd Journal: JAMA Date: 2002-11-13 Impact factor: 56.272
Authors: Tatyana Shamliyan; Jean F Wyman; Rema Ramakrishnan; François Sainfort; Robert L Kane Journal: Ann Intern Med Date: 2012-06-19 Impact factor: 25.391
Authors: Karin S Coyne; Chris C Sexton; Vasudha Vats; Christine Thompson; Zoe S Kopp; Ian Milsom Journal: Urology Date: 2011-01-22 Impact factor: 2.649
Authors: Leslee L Subak; Rena Wing; Delia Smith West; Frank Franklin; Eric Vittinghoff; Jennifer M Creasman; Holly E Richter; Deborah Myers; Kathryn L Burgio; Amy A Gorin; Judith Macer; John W Kusek; Deborah Grady Journal: N Engl J Med Date: 2009-01-29 Impact factor: 91.245
Authors: W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein Journal: World J Urol Date: 2002-11-15 Impact factor: 4.226
Authors: Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker Journal: BJU Int Date: 2009-11-12 Impact factor: 5.588
Authors: Michael L Ganz; Amy M Smalarz; Tracey L Krupski; Jennifer T Anger; Jim C Hu; Kim U Wittrup-Jensen; Chris L Pashos Journal: Urology Date: 2009-12-29 Impact factor: 2.649